Table 1.
Demographic and clinical characteristics of the patients
| Variable | AAC patients receiving PC treatment (n = 44) |
|---|---|
| Sex [male (%)] | 28 (63.6%) |
| Age (years) | 76 (65–82) |
| Length of stay (days) | 15 (8–27) |
| Intensive care unit stay | 16 (36.4%) |
| Grade II/III | 18 (40.9%)/26 (59.1%) |
| Cardiovascular dysfunction | 8 (18.2%) |
| Neurological dysfunction | 14 (31.8%) |
| Respiratory dysfunction | 10 (22.7%) |
| Renal dysfunction | 16 (36.4%) |
| aCCI | 5 (4–6) |
| Charlson comorbidity | |
| Prior myocardial infarction | 5 (11.4%) |
| Congestive heart failure | 4 (9.1%) |
| Diabetes | 12 (27.3%) |
| Cerebrovascular disease | 11 (25.0%) |
| Nonmetastatic solid tumor | 7 (15.9%) |
| Metastatic solid tumor | 7 (15.9%) |
| Moderate or severe renal disease | 4 (9.1%) |
| Ulcer disease | 3 (6.8%) |
| Preoperative jaundice | 9 (20.5%) |
| Common bile duct obstruction | 3 (6.8%) |
| Body temperature (℃) | 38.1 (37.1–39.0) |
| Preoperative fever (≥ 37.7℃) | 27 (61.4%) |
| Initial laboratory values | |
| Platelets (× 109 L) | 173.5 (117.5–322.0) |
| WBC counts (× 109 L) | 10.3 (7. 5–16.0) |
| Neutrophil granulocytes (%) | 83.2 (76.2–92.6) |
| ALT (U/L) | 30.5 (19.3–62.0) |
| STB (μmol/L) | 19.5 (13.0–30.7) |
| CB (μmol/L) | 1.6 (0–10.5) |
| UCB (μmol/L) | 6.6 (3.3–12.6) |
| Antibacterial treatment before PC | |
| Cephalosporin only | 14 (31.8%) |
| Carbapenem only | 9 (20.5%) |
| Fluoroquinolone only | 1 (2.3%) |
| Multi-drug combination | 17 (38.6%) |
aCCI age-adjusted Charlson comorbidity index; WBC White blood cells; ALT alanine aminotransferase; STB serum total bilirubin; CB conjugated bilirubin; UCB unconjugated bilirubin